Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Melanoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 100 (final count)
- Started
- Jun 26, 2020
- Main results expected
- Aug 25, 2025
- Fully finished
- Aug 25, 2025
- Results posted
- Aug 13, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Who Experienced an Adverse Event (AE)
Measured over: Up to approximately 39 months
Percentage of Participants Who Discontinued Study Treatment Due to an AE
Measured over: Up to 35 months
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI)
Measured over: Up to approximately 59 months
ORR Per RECIST 1.1 With 90% CI
Measured over: Up to approximately 59 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04305041 · record last updated 2026-09-01 · checked 2026-11-09 15:47 UTC